Anderson H, Scarffe J H, Swindell R, Crowther D
Eur J Cancer Clin Oncol. 1983 Mar;19(3):327-31. doi: 10.1016/0277-5379(83)90129-3.
Eighty-one patients with non-Hodgkin's lymphoma had serum beta 2-microglobulin (beta 2M) estimated at presentation. A significant association was found between beta 2M levels and stage of disease (P less than 0.001), presence of hepatomegaly (P less than 0.001) and bone marrow involvement (P less than 0.05). No association was found between the level of beta 2M and histological group, presence of splenomegaly, lymph-node masses greater than 5 cm in diameter, lymphocyte count or the presence of systemic B symptoms. Pretreatment levels of beta 2M did not help predict response to treatment and achievement of a complete remission, the length of remission obtained or survival.
81例非霍奇金淋巴瘤患者在初诊时测定了血清β2-微球蛋白（β2M）。发现β2M水平与疾病分期（P<0.001）、肝肿大（P<0.001）及骨髓受累（P<0.05）之间存在显著关联。未发现β2M水平与组织学类型、脾肿大、直径大于5cm的淋巴结肿块、淋巴细胞计数或全身B症状的存在之间存在关联。β2M的预处理水平无助于预测治疗反应及完全缓解的实现、缓解期的长短或生存期。
